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Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disease which has been
associated with an increased risk of adverse cardiovascular (CV) outcomes. Adequate strat-
ification of the CV risk is an issue of major importance in patients with HS. To analyze the
usefulness of carotid ultrasound (US) assessment for the CV disease risk stratification com-
pared with a traditional score, the Framingham risk score (FRS), in a series of patients with
HS.
Methods
Cross-sectional study of 60 patients with HS without history of CV events, diabetes mellitus
or chronic kidney disease. Information on CV risk factors was collected and the FRS was
calculated. Thus, the patients were classified into low, intermediate and high-CV disease
risk categories based on FRS. Carotid US was performed in all participants, and the pres-
ence of atherosclerotic plaques was considered as a marker of high CV risk.
Results
HS patients had a mean age of 45.1±10.2 years, and 55% were female. The median FRS
was 5.7 (IQR: 3.1–14.7). Twenty-four (40%) of the patients were classified into the low risk
group, 28 (46.7%) in the intermediate risk group, and 8 (13.3%) into the FRS-high risk cate-
gory. Noteworthy, carotid US revealed that about one-third of the patients (17/52; 32.6%) in
the FRS-based low and intermediate risk categories had carotid plaques, and, therefore,
they were reclassified into a high-risk category.
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Conclusion
CV risk in HS patients may be underestimated by using the FRS. Carotid US may be useful
to improve the CV risk stratification of patients with HS.
Introduction
Hidradenitis suppurativa (HS) or acne inversa is a chronic, inflammatory cutaneous disease
that affects aproximately 1% to 4% of the general population [1]. It is characterized by the for-
mation of multiples abscesses, nodules and scars in the apocrine gland-bearing areas of the
body. The most frequent anatomic sites involved are the axillary, inguinal, perianal, gluteal
and submammary regions [1,2]. The etiopathogenesis of HS is not completely understood.
Nevertheless, follicular occlusion due to hyperkeratosis is thought to be the primary event,
which can lead to subsequent follicular rupture and lymphohistiocytic inflammation [3], with
the involvement of the proinflammatory cytokines interleukin (IL)-1 beta, IL-10, Il-12, Il-23
and tumour necrosis factor alpha (TNF-α) [4,5].
HS has been associated with increased prevalence of traditional cardiovascular (CV) risk
factors, such as smoking, obesity, dyslipidemia, metabolic syndrome and diabetes mellitus [6–
11]. Moreover, an increased risk of adverse CV outcomes has also been reported in HS
patients. Thus, a recent population-based cohort study found a significantly higher risk of
major adverse CV events (MACEs), including myocardial infarction, ischemic stroke, and
CV-associated death in HS patients when compared to controls [12]. In keeping with these
findings, we and others have recently demonstrated that patients with HS have an increased
prevalence of subclinical atherosclerosis, which persists even after adjusting for classic CV risk
factors [13,14]. These observations suggest that HS itself may be an independent risk factor for
atherosclerotic CV disease, and support the hypothesis that, as well as in other chronic inflam-
matory conditions [15–17], the persistent systemic inflammation may be crucial to explain the
premature and accelerated atherogenesis in this disorder.
In clinical practice, CV risk assessment has been usually performed by risk scoring systems
that incorporate age, sex, diabetes mellitus, serum lipid levels, blood pressure and smoking
[18]. These equations are widely used to identify individuals at high risk for developing CV
disease events. The Framingham Risk Score (FRS) is a well established coronary risk assesment
tool that has been shown to be predictive of CV morbidity and mortality [19]. The Framing-
ham model predicts the risk of developing coronary heart disease (CHD) within 10-year, stra-
tifing patients into three categories (low, intermediate and high-risk) [19,20,21]. There is
evidence that risk estimates based on FRS data generalize well to other populations at similar
levels of risk, both in the USA and Europe [22]. Although FRS is a widely used method for esti-
mating CV disease risk, it has recognized limitations [23]. Thus, as well as other risk equations,
FRS was found to underestimate the actual CV risk in patients with several chronic inflamma-
tory diseases, such as rheumatoid arthritis [24], ankylosing spondilitis [25,26] and psoriasis
[27,28].
Several imaging techniques are currently available to disclose the presence of atherosclerotic
macrovascular disease. Carotid ultrasonography (US) is a validated tool for the evaluation of
subclinical atherosclerosis through the assessment of cIMT and atheroma plaques [29–31].
The finding of carotid atherosclerotic plaques was found to be a good predictor of CV events
in low and intermediate risk groups of individuals with non-rheumatic disorders [32], and
their presence automatically put the patient on a very high CV risk category [33].
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Taking together all these considerations, in the present study we have compared the CV
risk estimated by a traditional score, the FRS, with that obtained by adding carotid US assess-
ment of subclinical atherosclerosis in patients with HS. Thus, we aimed to determine if the use
of carotid US may improve the stratification of the CV risk of HS patients.
Patients and methods
Patients
In this cross-sectional study, 60 patients with a diagnosis of HS were recruited at the University
Hospital Marqués de Valdecilla in Santander, Spain. The diagnosis of HS was done by derma-
tologists in all patients.
For the purpose of this study, we used the methodology that we previously described in
detail [13]. Thus, patients with a history of CV events (CHD, cerebrovascular disease, heart
failure, and/or peripheral arterial disease) were excluded. Furthermore, patients with type 1
and type 2 diabetes mellitus were also excluded, since diabetes is considered as a CHD risk
equivalent. Furthermore, we did not include patients with chronic kidney disease (defined as a
glomerular filtration rate<60 ml/min/1.73 m2), since these are also considered a group with
high CV risk. We also excluded HS patients who had another concomitant inflammatory dis-
ease, such as inflammatory bowel disease, inflammatory arthritis (rheumatoid arthritis or
spondyloartropaties), connective tissue diseases (systemic lupus erythematosus or other auto-
immune diseases) or cutaneous inflammatory diseases (psoriasis or atopic dermatitis among
others).
A clinical examination was carried out in all patients. The severity of HS was assessed by
the HS Physician’s Global Assessment (HS-PGA), which includes 6 stages (scale 0–5) with
clear guidance for disease severity assessment [13,34]. According to HS-PGA, HS was classi-
fied as moderate-severe-very severe when PGA3. Moreover, information on disease duration
was also assessed in all patients.
The study was approved by the Ethical Committee of Cantabria (Spain). Written consent
was obtained from all participants.
Cardiovascular risk factors assessment
All patients provided information on their demographics, past medical history, smoking sta-
tus, family history of early CHD in first-degree relatives and use of antihypertensive medica-
tions and/or lipid-lowering agents. Traditional CV risk factors were defined as previously
reported [13]. Body height and weight, body mass index (BMI), systolic blood pressure (BP)
and diastolic BP were measured in all patients at the time of the study. Blood samples were
drawn after an overnight fast, and serum total cholesterol (TC), high-density lipoprotein cho-
lesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triglycerides, glucose, high-sen-
sitivity C-reactive protein (hs-CRP) levels, and erythrocyte sedimentation rate (ESR) were
assessed.
Framingham risk scoring
We used the ATP III charts [19] to calculate the 10-year CHD risk for each patient. Risk factors
considered were: age at the time of the study, gender, smoking, systolic BP, use of antihyper-
tensive treatment, and TC and HDL-c concentrations. As proposed by Greenland et al, [35]
each patient was classified into one of the following three risk categories: low risk (5%), inter-
mediate risk (6–20%) and high risk (>20%).
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Carotid ultrasound examination
As described in detail previously [13], the detection of carotid atherosclerotic plaques in the
extracranial tree was performed using a commercially available scanner, Mylab 70 Esaote
(Genoa, Italy) equipped with a 7 to 12 MHz linear transducer and the automated software-
guided technique radiofrequency-Quality Intima Media Thickness in real-time (QIMT,
Esaote, Maastricht, The Netherlands). Carotid atherosclerotic plaque was identified as recom-
mended in the Mannheim consensus, that is when a focal structure that encroaches into the
arterial lumen of at least 0.5 mm or 50% of the surrounding cIMT value or demonstrates a
thickness of>1.5 mm as measured from the media-adventitia interface of the intima-lumen
interface, is present [36]. The presence of carotid plaques was considered as the gold standard
of severe subclinical atherosclerosis.
Statistical analysis
Results were reported as mean ± standard deviation (SD), median and interquartile range
(IQR) or proportions as appropriate. The association of quantitative recorded variables with
carotid plaque was assessed by means of Student t-test or Mann-Whitney U-test, as appropri-
ate. Pearson chi-square test or Fisher exact test were used to compare qualitative variables.
The performance of the FRS in assessing plaque presence was determined by the area under
the curve (AUC) in ROC curve analysis. To determine clinically useful cutoff values in assess-
ing the presence of plaque, we set the sensitivity and specificity of FRS equation at 80% in
sequential analyses. We also determined the sensitivity and specificity when the conventional
cutoff values of 5% and 20% were used for the FRS in assessing plaque presence. Two-sided
p<0.05 was considered statistically significant. STATA 12/SE software (StataCorp, College Sta-
tion, TX) was used in all the calculations.
Results
Baseline characteristics
Sixty consecutive Caucasian patients with HS were studied. The baseline characteristics of the
study population according to the presence of plaque are listed in the Table 1. The mean age of
the patients at the time of the study was 45.1±10.2 years, and 55% were women. The median
(IQR) disease duration was 18 (10–27) years. Thirty-six patients (60%) were classified as mod-
erate-severe/very severe HS (HS-PGA3), and the remainder 24 (40%) as minimal-mild HS
(HS-PGA <3). Twenty-three (38.3%) patients were currently being treated with TNF
inhibitors.
Framingham risk score
The mean (IQR) FRS of the study population was 5.7 (3.1–14.7). There were 24 (40%) HS
patients who were classified into the FRS-low risk group, 28 (46.7%) into the intermediate risk
group, and 8 (13.3%) into the high risk category.
Carotid ultrasound findings
Carotid plaques were present in 22 HS patients (36.6%). As shown in the Table 1, those with
plaques were older (48.8±8.8 versus 42.9±10.5 years; p = 0.03) and had a significantly longer
disease duration (23.5 versus 15.5 years; p = 0.02) than those without. They had more com-
monly severe forms of HS (HS-PGA3), and were more frequently current smokers than HS
patients without carotid plaques. Also, cIMT values were significantly higher in patients with
plaques than those without (0.656±0.104 mm versus 0.603±0.093 mm; p = 0.04). The mean
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FRS for HS patients with carotid plaques was 7.9 (4.9–19.9), which was significantly higher
than the mean value for those without plaques [4.8 (2.8–11.3); p = 0.04].
Comparison between the FRS and carotid US assessment in the CV risk
stratification
The frequency of carotid plaques by each FRS-based category was calculated to estimate the
ability of the Framingham equation to correctly classify patients as having high CV risk. Five
(20.8%) of the HS patients who fulfilled the low CV risk category had carotid plaques, and
were reclassified into an ultrasound-based high-CV disease risk group. Moreover, 12 (42.9%)
of the patients from the FRS-based intermediate-risk category had also plaques, and so, they
were reclassified into an ultrasound-based high- CV disease risk group (Fig 1). Therefore,
Table 1. Baseline features of HS patients according to the presence of carotid plaque.
Total(n = 60) Without Plaque(n = 38) With Plaque(n = 22) p
Demographics
Age, years 45.1±10.2 42.9±10.5 48.8±8.8 0.03
Women 33 (55.0) 20 (52.6) 13 (59.1) 0.63
Weight, Kg 81.9±17.1 83.7±17.6 78.9±16.1 0.31
Conventional CV risk factors
Hypertension 11 (18.3) 6 (15.8) 5 (22.7) 0.51
Dyslipidemia 9 (15.0) 5 (13.5) 4 (18.2) 0.72
Systolic blood pressure, mm Hg 132.7±16.7 131.5±16.5 134.6±17.4 0.50
Diastolic blood pressure, mm Hg 80.7±9.7 80.9±9.9 80.5±9.5 0.89
Total cholesterol, mg/dl 188.8±31.7 187.2±31.0 191.5±33.4 0.62
LDL-cholesterol, mg/dl 117.8±32.3 115.9±31.1 121.1±34.8 0.55
HDL-cholesterol, mg/dl 51.1±16.7 51.2±16.4 50.8±17.6 0.93
Cholesterol/HDL-cholesterol ratio 3.97±1.21 3.9±1.2 4.1±1.3 0.65
Triglycerides, mg/dl 97.7±44.8 97.7±49.0 97.7±37.6 0.99
Current smoking 37 (61.7) 19 (50.0) 18 (81.8) 0.02
Body mass index > 30 Kg/m2 25 (41.7) 18 (47.4) 7 (31.9) 0.37
Family history of early CHD in first-degree relatives 7 (11.7) 5 (13.2) 2 (9.1) 0.96
CV drug use
Antihypertensive drugs 4 (6.7) 2 (5.3) 2 (9.1) 0.62
Lipid-lowering agents 7 (11.6) 4 (10.5) 3 (13.6) 0.96
Risk factor control
Blood pressure < 140/90 mmHg 41 (68.3) 26 (68.4) 15 (68.2) 0.98
LDL-cholesterol < 70 mg/dl 3 (5.0) 2 (5.3) 1 (4.5) 0.99
HS features
Duration, yrs 18.0 (10.0–26.8) 15.5 (7.0–25.0) 23.5 (15.3–30.3) 0.02
PGA (3) 36 (60.0) 19 (50.0) 17 (77.3) 0.04
CRP, mg/l 0.35 (0.15–0.74) 0.35 (0.16–0.72) 0.37 (0.15–0.89) 0.81
ESR, mm/1st h 13.5 (6.0–22.0) 9.0 (3.0–22.5) 15 (7.8–22.5) 0.27
cIMT, mm 0.622±0.099 0.603±0.093 0.656±0.104 0.04
Framingham score 5.7 (3.1–14.7) 4.8 (2.8–11.3) 7.9 (4.9–19.9) 0.04
PGA, physician global assessment; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SD, standard deviation; cIMT, carotid intima-media
thickness; CV, cardiovascular.Values are expressed as mean±SD, median (interquartile range) or percentages and compared by means of Chi2-test,
Mann-Whitney U-test, Student t-test or Fisher test as appropriate. Significant values are marked in bold.
https://doi.org/10.1371/journal.pone.0190568.t001
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carotid US correctly reclassified as high risk patients, about a third (17/52; 32.6%) of the
patients included in the intermediate or low risk categories according to FRS.
ROC curve analysis on the CVD risk equation-carotid plaque relations
ROC curve for the relationship between FRS and carotid plaque measured by US is shown in
the Fig 2. The AUC (95% CI) was 0.65 (0.51–0.80); p = 0.04. Table 2 shows that when sensitiv-
ity for the FRS was set at 80%, the cut-off value was 4.8%, with a corresponding specificity, pos-
itive predictive value (PPV), negative predictive value (NPV), and correct classification
percentage of 50%, 49%, 83% and 61%, respectively. When specificity was set at 80%, the cut-
off value was 13.3% and the corresponding sensitivity, PPV, NPV, and correct classification
percentage were 40%, 80%, 53%, and 65%, respectively. At a conventional high risk cut-off of
20% for FRS, the corresponding sensitivity, specificity, PPV, NPV and correct classification
percentage were 23%, 92%, 63%, 67% and 67%, respectively.
Discussion
The results observed in the current study indicate that a traditional CV risk algorithm, the
FRS, has limitations in its ability to correctly stratify subjects into CV disease risk groups and
underestimates the actual risk in patients with HS. A substantial number of HS patients who
were classified in the low and intermediate risk groups according to the FRS had atheroscle-
rotic plaques, and therefore, they were reclassified into a high-risk category, after carotid US
assessment was performed.
Atheromatous plaque formation indicates intimal pathological changes, and is considered a
later step in the atherogenesis process more closely linked to CHD risk factors and myocardial
infarction compared to increased cIMT [37]. Moreover, the detection of atherosclerotic pla-
ques increased the predicted CHD risk at any level of cIMT [30], and subjects with carotid pla-
ques should be automatically considered as very high CV disease risk individuals [26,33].
Fig 1. Frequency of carotid plaques by each Framingham risk score based category.
https://doi.org/10.1371/journal.pone.0190568.g001
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There are several possible reasons that could explain the discordance between the FRS and
carotid US findings. Firstly, CV scoring systems are aimed to predict the risk for CHD or total
CVD risk, but a significant percentage of patients with severe atherosclerosis will be missed
when those scoring systems are used as the initial risk assessment [38]. With respect to this,
the FRS predicts CV risk morbidity and mortality but it has not been tested for the prediction
of subclinical atherosclerosis. In this regard, the FRS uses only standard risk factors, but other
factors such as obesity, insulin resistance and metabolic syndrome also can contribute to the
development of atherosclerosis and are not captured in the scoring system [23,39].
Secondly, the problem of CV disease risk underestimation with these risk calculators is
increased in patients with chronic inflammatory diseases. In these patients, chronic systemic
inflammation may promote the development of endothelial cell dysfunction with the subse-
quent development of accelerated atherogenesis [13]. In this sense, several studies have shown
that the FRS and other CV risk algorithms often underestimate the CV risk in patients with
rheumatic diseases, such as rheumatoid arthritis and ankylosing spondylitis [24–26], when
tested against imaging findings of subclinical atherosclerosis. Moreover, a recent study
Fig 2. ROC curve for the relationship between Framingham risk score and carotid plaque.
https://doi.org/10.1371/journal.pone.0190568.g002
Table 2. Classification of Spanish patients with HS at Framingham risk equation cutoff values based on sensitivity or specificity set at 80% in
ROC analysis, or conventional recommendations.
Cutoff value (%) Sensitivity (%) Specificity (%) PPV(%) NPV(%) Correct classification (%)
Framingham score  4.8 80 (63–100) 50 (33–67) 49 (31–66) 83 (65–100) 61
 13.3 40 (18–63) 80 (65–93) 53 (26–79) 70 (55–85) 65
 20 23 (3–42) 92 (82–100) 63 (23–100) 67 (54–81) 67
PPV, Predictive positive value; NPV, Negative predictive value. CI 95% in parentheses.
https://doi.org/10.1371/journal.pone.0190568.t002
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revealed that 55.9% of psoriatic patients with intermediate CV risk according to the FRS had
carotid plaques [27]. Our results in patients with HS confirm and extend these findings
observed in patients with other chronic inflammatory conditions.
Our study shows that carotid US may be useful as an additional tool to improve the sensitiv-
ity of the FRS to detect HS patients at high CV disease risk. Because of that, we feel that the use
of non-invasive imaging techniques to disclose the presence of subclinical atherosclerosis may
complement currently used risk assessment tools. An adequate stratification of HS patients
would provide a more tight CV disease risk factor control in a clinically relevant proportion of
these patients that are included in the categories of low and intermediate estimated CV disease
risk according to FRS. It is of particular relevance if we consider that patients at high CV risk
as evidenced by carotid US-determined plaque presence require intensive CV disease risk
management. In this regard, the European Guidelines on cardiovascular disease prevention in
clinical practice recommend intensive lipid lowering treatment with a LDL cholesterol target
of<1.8 mmol/L (<70 mg/dl) in individuals with very high CV disease risk [33]. In this regard,
our data also highlight that low FRS cut-off values, close to 5%, have a high sensitivity to detect
high-risk subclinical atherosclerosis in patients with HS. In fact, with a FRS cut-off value of
20%, sensitivity was further reduced to 23%.
The limitations of our study include an overall small size sample and those inherent to a
cross-sectional design. Prospective longitudinal studies are needed to determine whether
reclassification to a higher category actually translates to increased CV events in patients with
HS.
In summary, the results of the current study suggest that carotid US may improve CV dis-
ease risk stratification of patients with HS. The use of this non-invasive technique allows us to
identify HS individuals at high risk who would benefit of having a strict management of CV
risk factors. Based on our data, we recommended the use of carotid US in HS-patients with an
intermediate risk for cardiovascular disease (40% of prevalence of carotid plaques in our
series). Low-risk HS individuals aged 50 years and older, active smokers, with severe (PGA
3) or longstanding disease (>20 years) should be considered for carotid ultrasonography
assessment according to an individualized clinical evaluation.
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